News | News By Subject | News by Disease News By Date | Search News

Melanoma News Articles

Get Our FREE
Industry eNewsletter
email:    
Top Breaking News
Bristol-Myers Squibb (BMY)'s Opdivo Prevails in Phase III Melanoma Trial     7/6/2017
Array BioPharma (ARRY) Has a Potential Blockbuster Melanoma Drug On Its Hands     2/13/2017
Two Deaths Linked to Bristol-Myers Squibb (BMY)'s Yervoy-Opdivo Combo     11/3/2016
Scancell (SCNLF) Delays Melanoma Trial 9 to 12 Months to Whip Up New Batch of Cancer Vaccine     7/7/2016
Scancell (SCNLF) Suspends Dosing in Melanoma Trial Due to Quality Issues     6/17/2016
European Commission (EC) Approves the First and Only Immuno-Oncology Combination, Bristol-Myers Squibb (BMY)’s Opdivo (Nivolumab) + Yervoy (Ipilimumab) Regimen, for Treatment of Advanced Melanoma     5/11/2016
Investors Unhappy as Caladrius Biosciences (CLBS) Kills Phase III Oncology Program, Lays Off 40 in SoCal     1/8/2016
Array BioPharma (ARRY) Surges as Binimetinib Meets Goals in Late-Stage Study     12/16/2015
FDA Grants Full U.S. Approval for Novartis AG (NVS)' Targeted Skin Cancer Combo     11/23/2015
FDA Approves Daiichi Sankyo, Plexxikon's Cobimetinib In Combination With Zelboraf for Advanced Melanoma Patients     11/11/2015
FDA Green Lights Genentech (RHHBY)'s Vemurafenib/Cobimetinib Combo for Melanoma     11/10/2015
Investors Elated as Amgen (AMGN) Wins FDA Approval for First-of-Its-Kind Cancer Killing Virus Drug     10/30/2015
Investors Hold Their Breath as Amgen (AMGN) Inches Toward U.S. Approval for Its New Cancer Immunotherapy T-Vec     10/26/2015
Exelixis (EXEL), Genentech (RHHBY)'s Cobimetinib Succeeds in Pivotal Phase III Trial     10/8/2015
FDA Green Lights Bristol-Myers Squibb (BMY)'s Drug Combo for Metastatic Melanoma     10/2/2015

News from Around the Web
Hemopurifier Filters Ebola, Hep C, Metastatic Melanoma: Interview With James A. Joyce, CEO Of Aethlon Medical (AEMD)     7/21/2017
New Microscopic Technique Could Help Detect, Diagnose Metastatic Melanomas, Royal Society Of Chemistry Reveals     5/5/2017
New Technique Spots Pheomelanin In Pale Patients At Risk Of Dangerous Melanoma, Massachusetts General Hospital Reveals     3/8/2017
Genetic Causes Of Higher Melanoma Risk In Men Discovered, Universitat Jaume I de Castellón Reveals     7/22/2016
Microneedle Patch Delivers Localized Cancer Immunotherapy To Melanoma, North Carolina State University Study     3/25/2016
Pharma's Big New Cancer Drug May Be An Old Red Dye     2/26/2016
Vitamin B3 Derivative Cuts Risk Of New Skin Cancers, University of Sydney Study     10/22/2015
Could Laser Skin Test Replace Biopsy For Melanoma? Lancaster University Study     8/24/2015
Coffee Lowers Deadly Skin Cancer Risk, Yale School Of Public Health Study     1/22/2015
Sunscreens Do Not Fully Protect Against Skin Cancer, University Miguel Hernández Study     7/16/2014
Viagra Poses Cancer Risk For Men, JAMA Reveals     6/6/2014
Pine Bark Substance Could Treat Melanoma, Penn State Hershey Melanoma Center Study     5/22/2014
Link Between Viagra And Melanoma Discovered, JAMA Reveals     4/11/2014
Melanoma In Families Linked To Mutations In One Gene, University of Leeds Study     4/3/2014
Sleep Apnea Severity Predicts Aggressiveness of Melanoma, Hospital de Valme Study     9/9/2013

Press Releases
Sensus Healthcare (SRTSU) Receives Regulatory Approval To Sell The SRT-100 In China For The Treatment And Prevention Of Keloids     7/26/2017
Bristol-Myers Squibb (BMY) Release: FDA Expands Approval Of Yervoy (Ipilimumab) To Include Pediatric Patients 12 Years And Older With Unresectable Or Metastatic Melanoma     7/24/2017
iCAD (ICAD) Announces Positive Study Results Comparing Use Of Company’s Xoft® Axxent® Electronic Brachytherapy (EBx) System To Mohs Surgery In Treatment Of Early-Stage Non-Melanoma Skin Cancer     7/19/2017
Castle Biosciences’ Uveal Melanoma Test Receives Positive Medicare Local Coverage Determination And Commercial Insurance Positive Coverage Policies     7/18/2017
Array BioPharma (ARRY) Submits New Drug Applications To FDAFor Binimetinib And Encorafenib In Advanced Melanoma     7/5/2017
Human Longevity Announces Agreement With Merck KGaA (MKGAF.PK), Darmstadt, Germany To Engage In Cancer Biomarker Discovery In Advanced Melanoma     6/15/2017
OncoSec Medical Granted Orphan Drug Designation From The U.S. FDA For The Treatment Of Unresectable Metastatic Melanoma     6/9/2017
Amgen (AMGN) Presents New Phase II Data On IMLYGIC (Talimogene Laherparepvec) Investigational Combination At ASCO 2017     6/5/2017
Bristol-Myers Squibb (BMY) Release: First Presentation Of Efficacy Data From Checkmate -204 Evaluating The Combination Of Opdivo (Nivolumab) And Yervoy (Ipilimumab)Demonstrates Anti-Tumor Activity In Advanced Melanoma Patients With Brain Metastases     6/5/2017
Celldex (CLDX) Presents Promising Overall Survival Data From Phase II Study Of Single-Agent Glembatumumab Vedotin In Patients With Checkpoint-Refractory Metastatic Melanoma     6/5/2017
Novartis AG (NVS) Landmark Study Of Tafinlar + Mekinist Demonstrates Durable Survival Benefit At Five Years In Patients With BRAF Mutation-Positive Metastatic Melanoma     6/5/2017
Castle Biosciences Presents Three New Clinical Studies At ASCO 2017 Highlighting The Accuracy And Performance Of The Decisiondx-Melanoma Gene Expression Profile Test For Cutaneous Melanoma     6/5/2017
Merck & Co. (MRK) Release: With Nearly Three Years Of Follow-Up, KEYTRUDA (Pembrolizumab) Data Demonstrated Improved Survival Benefit Compared To Ipilimumab In Advanced Melanoma     6/2/2017
BerGenBio AS Announces Start Of Randomized Phase I/II Trial Assessing Selective AXL Inhibitor BGB324 In Combination With Current Therapies In Melanoma     5/22/2017
NYU Langone Medical Center Release: Erectile Dysfunction Medicines Do Not Cause Melanoma, Analysis Of Large Studies Finds     5/19/2017

//-->